Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Editorial

Targeting Protein Phosphatase 1 in Heart Failure

Hunter C. Champion
Download PDF
https://doi.org/10.1161/01.RES.0000164359.95588.25
Circulation Research. 2005;96:708-710
Originally published April 14, 2005
Hunter C. Champion
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics

Jump to

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

See related article, pages 756–766

Over the past three decades the treatment of heart failure has shifted from a palliative care approach to a more successful focus on neurohormonal modulation through drugs that inhibit β-adrenergic, angiotensin, and aldosterone signaling. Despite these relatively recent advances, the clinical syndrome of heart failure remains progressive in nature. This observation begs the question as to a unifying aberrancy in cardiomyocyte phenotype that occurs in heart failure. More recently great attention has been paid to the alterations in calcium handling and has typically been associated with calcium-transients that are of a lower amplitude and slower decline than normal cardiomyocytes.1–4 This slower decline has been attributed to a decrease in the Ca2+ uptake into the sarcoplasmic reticulum (SR); and particularly with the relative role of phospholamban (PLB) and the SR Ca2+-ATPase (SERCA).4,5 Whereas previous work has successfully targeted PLB and SERCA in the investigational treatment of heart failure in mouse, rat, and human myocytes, more recent work has focused on the potential modulators of this system to elucidate the pathophysiologic changes that result in aberrant calcium handling.2–6

In this issue, Pathak and del Monte et al show that targeted inhibition of protein phosphatase 1 (PP1) by increased activity of its inhibitor, inhibitor-1 in the heart, results in enhanced contractility and is protective against the development of cardiac hypertrophy and heart failure stimulated by hemodynamic load.7 In failing hearts, the downregulation of adrenergic receptor and cAMP-dependent protein kinase signaling leads to the inactivation of inhibitor-1 which, in turn, results in increased activity of PP1.7,8 This activation of PP1 leads to the dephosphorylation of phospholamban thus reducing calcium uptake by SERCA-2a. In an important series of experiments in transgenic mice and using gene transfer in rats, Kranias, Hajjar, and colleagues now show that the targeted inhibition of protein phosphatase 1 by overexpression of inhibitor-1 enhances cardiac contractility under normal hemodynamic conditions as well as in response to adrenergic stimulation with isoproterenol. Moreover, the authors show that targeted gene transfer of active inhibitor-1 in rats results in marked attenuation of the functional and morphometric changes associated with chronic pressure overload.

As a first step, the investigators determined the influence of the expression of a constitutively active, truncated analog of inhibitor-1 that was targeted to the cardiac myocytes. Both intact hearts and isolated myocytes expressing this activated inhibitor-1 exhibited enhanced contractility under basal conditions and augmented responsiveness to adrenergic stimulation. This enhanced contractility was associated with increased phosphorylation of phospholamban and the subsequent enhanced SERCA-2a activity.

When subjected to chronic pressure overload, mice expressing active inhibitor-1 exhibited less cardiac hypertrophy and interstitial fibrosis than wild-type mice. These beneficial effects were associated with a reduction in the activation of the MAP-kinase hypertrophic pathway, ERK1/2, but p38 activation was unchanged. Although phospholamban phosphorylation was reduced in the banded transgenic mice when compared with sham controls, this activation of the SERCA modulator remained higher than wild-type banded mice.

Because the clinical treatment of heart failure deals with preexisting conditions and is not generally directed at the prevention of disease, the authors turned to a model of chronic pressure overload–induced heart failure in the rat. In this series of experiments, adult rats subjected to aortic banding were transfected with a virus encoding the active inhibitor-1. Rats transfected with inhibitor-1 had a marked improvement in both systolic and diastolic left ventricular function. As with the studies in transgenic mice, this improvement in function was associated with an increase in SERCA-2a activity, albeit the total protein levels were reduced with heart failure.

This novel series of experiments further highlights the role of protein phosphatases in modulating not only cardiac function, but also a role in the response to stress. In recent years there has been a great deal of attention paid to intracellular mediators of hypertrophic signaling cascades, and data have been inferred to link some of these proteins and transcription factors to the early development of heart failure.2–6 To that end, many protein kinases and their substrates that mediate the expression of hypertrophy and progression to heart failure have been relatively well characterized. Much less relative attention has been paid to the protein phosphatases in this regard. The major Ser/Thr phosphatases such as type 1, type 2A, and type 2B (calcineurin) are a highly homologous family of proteins that play a critical role in the modulation of cardiac contractility, the expression of hypertrophy, and the progression to heart failure.7–11 In human and experimental heart failure, the type 1 phosphatase which is associated with the sarcoplasmic reticulum is activated through the dephosphorylation of its inhibitor protein, inhibitor-1.7,8 Molkentin and colleagues have recently shown that protein kinase C-alpha (PKC-α) plays a critical role in the regulation of cardiac contractility and the propensity of the heart to develop heart failure.9 Importantly, the major target of PKC-α is the phosphorylation, and resulting activation, of inhibitor-1. The findings of the present study and prior studies with PKC-α reinforce this important link between inhibitor-1, protein-phosphatase 1, and the expression of heart failure (Figure).7–9

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

The β-adrenergic receptor couples with an inhibiting receptor kinase (BARK) and the stimulatory G-protein/adenylate cyclase complex (GSα-AC). Normal activation of calcium by this pathway increases cAMP synthesis and stimulates protein kinase A (PKA), which phosphorylates I-1 protein to act as an inhibitor of phosphatase PP-1. PKA phosphorylates phospholamban (PLB) to enhance sarcoplasmic reticular (SR) calcium uptake, which is further augmented by the decline in PP-1 activity. In settings in which PKCα is stimulated by calcium or various stress agonists, I-1 is phosphorylated at a different site, resulting in stimulation of PP-1 and reduced phosphorylation of PLB. The result is reduced calcium uptake by the sarcoplasmic reticulum and diminished contractile force. NCX indicates sodium/calcium exchanger; SERCA-2a, sarcoplasmic reticular ATPase. It is unclear whether PP-1 may affect pathways other than PLB/SERCA2a, such as NCX, Bcl-2, or other pathways associated with cardiac hypertrophy and the progression to heart failure.

Although both PKC-α and protein phosphatase 1 appear to be integrally linked under conditions of heart failure, where PKC-α expression and activity is increased, there is a divergence in the role of these proteins in the expression of cardiac hypertrophy where protein phosphatase 1 activity is altered under conditions in which there is no change in PKC-α.9 Data from the present study showing marked prevention of cardiac hypertrophy under conditions of increased inhibitor-1 expression support this hypothesis and may suggest that the major influence on inhibitor-1 phosphorylation under conditions of hypertrophy is from PKA activation or another protein kinase. The present data support the hypothesis that although the stimuli may be different in hypertrophy and heart failure, the common pathway involves inhibitor-1 and the influence on protein phosphatase 1. Moreover, the observation that the hearts of transgenic mice overexpressing inhibitor-1 are normal in size and histology but have enhanced contractility suggests that under basal conditions, the role of inhibitor 1 and protein phosphatase 1 is relegated to contractility. However, under stress from pressure overload, the role for this pathway also involves the expression of hypertrophy, remodeling, and the progression to heart failure.

Unresolved, however, is the mechanism by which protein phosphatase 1 modulates hypertrophy signaling. It is unlikely that all of the observed effects are mediated solely by the effects of protein phosphatase 1 and its action at the level of its influence on phospholamban. Intriguingly, when Kranias and colleagues banded mice that were deficient in phospholamban, the greater contractility provided through enhanced SERCA-2a function did not impact the expression of cardiac hypertrophy nor the influence on the progression to heart failure.12 Furthermore, the genetic lack of phospholamban does not improve ventricular function in other models of heart failure such as overexpression of tropomodulin,13 Gαq,14 mutant myosin binding protein C,15 or TNFα overexpression,16 despite the fact that prolonged myocyte calcium transients are rescued. Although it is possible that the differences between the present article and previous reports rest in the differences between genetically altered mice and models used, it is unlikely that resolution of one aspect of heart failure (ie, calcium cycling) is sufficient to prevent or erase the heart failure phenotype. It is possible that enhanced inhibitor-1 expression/activity results in multiple benefits by providing some resolution of calcium transients through its effect on phospholamban, but also by other downstream effects on signaling pathways associated with the heart failure such as PKC17 and NCX118 or with cell survival through apoptosis regulators such as Bcl-2.19 The present publication opens the door for an intriguing study to determine these potential novel downstream targets of inhibitor 1 and/or protein phosphatase 1 that may work in conjunction with the better understood effect on calcium cycling.

The targeting of modulators of calcium handling proteins, and specifically the role of protein phosphatases in this modulation, have recently been thought of as therapeutic targets for the treatment of heart failure with the relatively recent observations that phospholamban and SERCA-2a play a central role in the disease. How should we integrate the present data with the previously published body of evidence? It would seem that a disease that is as highly integrated as heart failure would not be one in which a single approach (ie, phospholamban ablation) would erase this clinical syndrome that is overwhelmingly complex. The present data support this hypothesis by demonstrating that working upstream of phospholamban may afford an additional benefit in the targeting of heart disease. As with the modulation of PKC-α, the prevention and treatment of heart failure by stimulation of inhibitor 1 may be more amenable to pharmacological targeting than the direct targeting of phospholamban or SERCA-2a.

Footnotes

  • The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

References

  1. ↵
    Bers DM. Cardiac excitation-contraction coupling. Nature. 2002; 415: 198–205.
    OpenUrlCrossRefPubMed
  2. ↵
    Houser SR, Margulies KB. Is depressed myocyte contractility centrally involved in heart failure? Circ Res. 2003; 92: 350–358.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Piacentino V 3rd, Weber CR, Chen X, Weisser-Thomas J, Margulies KB, Bers DM, Houser SR. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res. 2003; 92: 651–658.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 2003; 4: 566–577.
    OpenUrlCrossRefPubMed
  5. ↵
    Gupta RC, Shimoyama H, Tanimura M, Nair R, Lesch M, Sabbah HN. SR Ca(2+)-ATPase activity and expression in ventricular myocardium of dogs with heart failure. Am J Physiol. 1997; 273: H12–H18.
    OpenUrlPubMed
  6. ↵
    Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003; 65: 45–79.
    OpenUrlCrossRefPubMed
  7. ↵
    Pathak A, del Monte F, Zhao W, Schultz J, Lorenz JN, Bodi I, Weiser D, Hahn H, Carr AN, Syed F, Mavila N, Jha L, Qian J, Marreez Y, Gouoli C, McGraw DW, Heist EK, Guerrero JL, DePaoli-Roach AA, Hajjar RJ, Kranias EG. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res. 2005; 96: 756–766.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Carr AN, Schmidt AG, Suzuki Y, del Monte F, Sato Y, Lanner C, Breeden K, Jing SL, Allen PB, Greengard P, Yatani A, Hoit BD, Grupp IL, Hajjar RJ, DePaoli-Roach AA, Kranias EG. Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol. 2002; 22: 4124–4135.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, Kimball TF, Lorenz JN, Nairn AC, Liggett SB, Bodi I, Wang S, Schwartz A, Lakatta EG, DePaoli-Roach AA, Robbins J, Hewett TE, Bibb JA, Westfall MV, Kranias EG, Molkentin JD. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med. 2004; 10: 248–254.
    OpenUrlCrossRefPubMed
  10. ↵
    Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998; 93: 215–228.
    OpenUrlCrossRefPubMed
  11. ↵
    Gergs U, Boknik P, Buchwalow I, Fabritz L, Matus M, Justus I, Hanske G, Schmitz W, Neumann J. Overexpression of the catalytic subunit of protein phosphatase 2A impairs cardiac function. J Biol Chem. 2004; 279: 40827–40834.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Kiriazis H, Sato Y, Kadambi VJ, Schmidt AG, Gerst MJ, Hoit BD, Kranias EG. Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis. Cardiovasc Res. 2002; 53: 372–381.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Delling U, Sussman MA, Molkentin JD. Re-evaluating sarcoplasmic reticulum function in heart failure. Nat Med. 2000; 6: 942–943.
    OpenUrlCrossRefPubMed
  14. ↵
    Song Q, Schmidt AG, Hahn HS, Carr AN, Frank B, Pater L, Gerst M, Young K, Hoit BD, McConnell BK, Haghighi K, Seidman CE, Seidman JG, Dorn GW 2nd, Kranias EG. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest. 2003; 111: 859–867.
    OpenUrlCrossRefPubMed
  15. ↵
    Freeman K, Lerman I, Kranias EG, Bohlmeyer T, Bristow MR, Lefkowitz RJ, Iaccarino G, Koch WJ, Leinwand LA. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest. 2001; 107: 967–974.
    OpenUrlCrossRefPubMed
  16. ↵
    Janczewski AM, Zahid M, Lemster BH, Frye CS, Gibson G, Higuchi Y, Kranias EG, Feldman AM, McTiernan CF. Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model. Cardiovasc Res. 2004; 62: 468–480.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    duBell WH, Rogers TB. Protein phosphatase 1 and an opposing protein kinase regulate steady-state L-type Ca2+ current in mouse cardiac myocytes. J Physiol. 2004; 556: 79–93.
    OpenUrlCrossRefPubMed
  18. ↵
    Schulze DH, Muqhal M, Lederer WJ, Ruknudin AM. Sodium/calcium exchanger (NCX1) macromolecular complex. J Biol Chem. 2003; 278: 28849–28855.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Garcia A, Cayla X, Guergnon J, Dessauge F, Hospital V, Rebollo MP, Fleischer A, Rebollo A. Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis. Biochimie. 2003; 85: 721–726.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
April 15, 2005, Volume 96, Issue 7
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Targeting Protein Phosphatase 1 in Heart Failure
    Hunter C. Champion
    Circulation Research. 2005;96:708-710, originally published April 14, 2005
    https://doi.org/10.1161/01.RES.0000164359.95588.25

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Targeting Protein Phosphatase 1 in Heart Failure
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    Targeting Protein Phosphatase 1 in Heart Failure
    Hunter C. Champion
    Circulation Research. 2005;96:708-710, originally published April 14, 2005
    https://doi.org/10.1161/01.RES.0000164359.95588.25
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured